Richard A. Gonzalez

Before leading AbbVie, Richard A. Gonzalez built a multi-decade career at Abbott Laboratories, joining the company in 1977. He rose through the ranks in various leadership roles, eventually becoming President and Chief Operating Officer. His deep operational experience in the pharmaceutical and medical device sectors equipped him with the strategic foresight necessary to orchestrate one of the largest corporate spin-offs in healthcare history.

Richard A. Gonzalez served as AbbVie's founding Chairman and CEO from its inception in 2013 following its spin-off from Abbott Laboratories. Under his leadership, AbbVie transitioned from a division highly dependent on a single blockbuster drug (Humira) into a diversified, standalone global biopharmaceutical leader. He aggressively expanded the company's footprint in immunology, oncology, and neuroscience, executing complex, multi-billion-dollar strategic acquisitions, most notably the $63 billion purchase of Allergan in 2020. This acquisition dramatically reduced AbbVie's reliance on Humira just before its patent cliff, ensuring long-term revenue stability. Gonzalez's tenure is defined by his ability to navigate patent expirations, regulatory hurdles, and large M&A integration, ultimately generating large shareholder value before his transition to Executive Chairman in 2024.